Angela L Duker1, Dagmar Kinderman2, Christy Jordan3, Tim Niiler4, Carissa M Baker-Smith5, Louise Thompson6, David A Parry7, Ricki S Carroll1, Michael B Bober8. 1. Skeletal Dysplasia Program, Division of Orthogenetics, Nemours/Alfred I. duPont Hospital for Children, 1600 Rockland Road, Wilmington, DE, 19803, USA. 2. Department of Research, Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE, USA. 3. Potentials Foundation, Sandoval, IL, USA. 4. Gait Laboratory, Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE, USA. 5. Department of Cardiology, Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE, USA. 6. The South East of Scotland Clinical Genetic Service, Western General Hospital, Edinburgh, UK. 7. MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, UK. 8. Skeletal Dysplasia Program, Division of Orthogenetics, Nemours/Alfred I. duPont Hospital for Children, 1600 Rockland Road, Wilmington, DE, 19803, USA. mbober@nemours.org.
Abstract
BACKGROUND: Microcephalic osteodysplastic primordial dwarfism type II (MOPDII) is the most common form of primordial dwarfism, caused by bialleic mutations in the pericentrin gene (PCNT). Aside from its classic features, there are multiple associated medical complications, including a well-documented risk of neurovascular disease. Over the past several years, it has become apparent that additional vascular issues, as well as systemic hypertension and kidney disease may also be related to MOPDII. However, the frequency and extent of the vasculopathy was unclear. To help address this question, a vascular substudy was initiated within our Primordial Dwarfism Registry. RESULTS: Medical records from 47 individuals, living and deceased, ranging in age from 3 to 41 years of age were interrogated for this purpose. Of the total group, 64% were diagnosed with moyamoya, intracranial aneurysms, or both. In general, the age at diagnosis for moyamoya was younger than aneurysms, but the risk for neurovascular disease was throughout the shortened lifespan. In addition to neurovascular disease, renal, coronary and external carotid artery involvement are documented. 43% of the total group was diagnosed with hypertension, and 17% had myocardial infarctions. A total of 32% of the entire cohort had some form of chronic kidney disease, with 4% of the total group necessitating a kidney transplant. In addition, 38% had diabetes/insulin resistance. Ages of diagnoses, treatment modalities employed, and location of vasculopathies were notated as available and applicable, as well as frequencies of other comorbidities. CONCLUSIONS: It is now clear that vascular disease in MOPDII is global and screening of the cardiac and renal vessels is warranted along with close monitoring of blood pressure. We recommend a blood pressure of 110/70 mmHg as a starting point for an upper limit, especially if the individual has a history of neurovascular disease, chronic kidney disease and/or diabetes. Additionally, providers need to be at high alert for the possibility of myocardial infarctions in young adults with MOPDII, so that appropriate treatment can be initiated promptly in an acute situation.
BACKGROUND:Microcephalic osteodysplastic primordial dwarfism type II (MOPDII) is the most common form of primordial dwarfism, caused by bialleic mutations in the pericentrin gene (PCNT). Aside from its classic features, there are multiple associated medical complications, including a well-documented risk of neurovascular disease. Over the past several years, it has become apparent that additional vascular issues, as well as systemic hypertension and kidney disease may also be related to MOPDII. However, the frequency and extent of the vasculopathy was unclear. To help address this question, a vascular substudy was initiated within our Primordial Dwarfism Registry. RESULTS: Medical records from 47 individuals, living and deceased, ranging in age from 3 to 41 years of age were interrogated for this purpose. Of the total group, 64% were diagnosed with moyamoya, intracranial aneurysms, or both. In general, the age at diagnosis for moyamoya was younger than aneurysms, but the risk for neurovascular disease was throughout the shortened lifespan. In addition to neurovascular disease, renal, coronary and external carotid artery involvement are documented. 43% of the total group was diagnosed with hypertension, and 17% had myocardial infarctions. A total of 32% of the entire cohort had some form of chronic kidney disease, with 4% of the total group necessitating a kidney transplant. In addition, 38% had diabetes/insulin resistance. Ages of diagnoses, treatment modalities employed, and location of vasculopathies were notated as available and applicable, as well as frequencies of other comorbidities. CONCLUSIONS: It is now clear that vascular disease in MOPDII is global and screening of the cardiac and renal vessels is warranted along with close monitoring of blood pressure. We recommend a blood pressure of 110/70 mmHg as a starting point for an upper limit, especially if the individual has a history of neurovascular disease, chronic kidney disease and/or diabetes. Additionally, providers need to be at high alert for the possibility of myocardial infarctions in young adults with MOPDII, so that appropriate treatment can be initiated promptly in an acute situation.
Authors: Joseph T Flynn; David C Kaelber; Carissa M Baker-Smith; Douglas Blowey; Aaron E Carroll; Stephen R Daniels; Sarah D de Ferranti; Janis M Dionne; Bonita Falkner; Susan K Flinn; Samuel S Gidding; Celeste Goodwin; Michael G Leu; Makia E Powers; Corinna Rea; Joshua Samuels; Madeline Simasek; Vidhu V Thaker; Elaine M Urbina Journal: Pediatrics Date: 2017-08-21 Impact factor: 7.124
Authors: Anita Rauch; Christian T Thiel; Detlev Schindler; Ursula Wick; Yanick J Crow; Arif B Ekici; Anthonie J van Essen; Timm O Goecke; Lihadh Al-Gazali; Krystyna H Chrzanowska; Christiane Zweier; Han G Brunner; Kristin Becker; Cynthia J Curry; Bruno Dallapiccola; Koenraad Devriendt; Arnd Dörfler; Esther Kinning; André Megarbane; Peter Meinecke; Robert K Semple; Stephanie Spranger; Annick Toutain; Richard C Trembath; Egbert Voss; Louise Wilson; Raoul Hennekam; Francis de Zegher; Helmuth-Günther Dörr; André Reis Journal: Science Date: 2008-01-03 Impact factor: 47.728
Authors: M Willems; D Geneviève; G Borck; C Baumann; G Baujat; E Bieth; P Edery; C Farra; M Gerard; D Héron; B Leheup; M Le Merrer; S Lyonnet; D Martin-Coignard; M Mathieu; C Thauvin-Robinet; A Verloes; L Colleaux; A Munnich; V Cormier-Daire Journal: J Med Genet Date: 2009-07-29 Impact factor: 6.318
Authors: Emily D Parker; Alan R Sinaiko; Patrick J O'Connor; Heidi Ekstrom; Deepika Appana; Jerry Amundson; Elyse Olshen Kharbanda Journal: Am J Epidemiol Date: 2015-12-08 Impact factor: 4.897
Authors: Judith G Hall; Christina Flora; Charles I Scott; Richard M Pauli; Kimi I Tanaka Journal: Am J Med Genet A Date: 2004-09-15 Impact factor: 2.802
Authors: Mark J Sarnak; Kerstin Amann; Sripal Bangalore; João L Cavalcante; David M Charytan; Jonathan C Craig; John S Gill; Mark A Hlatky; Alan G Jardine; Ulf Landmesser; L Kristin Newby; Charles A Herzog; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Thomas H Marwick Journal: J Am Coll Cardiol Date: 2019-10-08 Impact factor: 24.094
Authors: D Hettiarachchi; S M V Subasinghe; G G Anandagoda; Hetalkumar Panchal; P S Lai; V H W Dissanayake Journal: BMC Med Genomics Date: 2022-04-14 Impact factor: 3.063